Clinical Trials (Phase III)
Filter News
Found 14,740 articles
-
Pfizer and Eli Lilly and Company announced top-line results from a Phase III clinical trial of two doses of tanezumab in moderate-to-severe osteoarthritis (OA) of the hip or knee.
-
Pharma and biotechs from across the globe share news, pipeline updates, with stories from Vetter, Atomwise, Tessa, GenSight, and more.
-
Pfizer and Lilly Announce Top-Line Results From Long-Term Phase 3 Study of Tanezumab in Patients With Osteoarthritis
4/18/2019
Pfizer Inc. (NYSE:PFE) and Eli Lilly and Company (NYSE:LLY) today announced top-line results from a Phase 3 study evaluating tanezumab 2.5 mg and 5 mg.
-
Soligenix Achieves Significant Enrollment Milestone for its Pivotal Phase 3 Clinical Trial of SGX942 in the Treatment of Oral Mucositis in Head and Neck Cancer
4/18/2019
Enrollment Sufficient to Support the Interim Efficacy Analysis
-
AveXis, a Novartis company, announced interim data from its Phase III STR1VE clinical trial of Zolgensma (onasemnogene abeparvovec-xioi) in spinal muscular atrophy (SMA) Type 1.
-
Cool Science News! We Want to Know
4/17/2019
The life science industry is continually making advancements in every area! We want to know what cool science innovations are currently in progress and the professionals behind them. -
April 17, 2019 is the 29th World Hemophilia Day, a designated day to create awareness of the disease. Hemophilia is one of a number of bleeding disorders. The blood of people with hemophilia does not clot normally as the result of insufficient clotting factor. As a result, they can bleed for a lo...
-
Inovio's Phase 3 HPV Immunotherapy Selected As "Best Therapeutic Vaccine" at World Vaccine Congress
4/17/2019
The Vaccine Industry Excellence Awards honor outstanding vaccine and immunotherapy advancements and achievements across the worldwide industry as judged by a panel of global biotech industry stakeholders.
-
GenSight Biologics Reports Positive Follow-up Results at Week 72 of the RESCUE Phase III Clinical Trial of GS010 in Leber Hereditary Optic Neuropathy (LHON)
4/17/2019
GS010-treated eyes showed continuous recovery of visual functions from nadir (worst vision post-treatment) in both best-corrected visual acuity (BCVA) and contrast sensitivity (CS)
-
AveXis data reinforce effectiveness of Zolgensma® in treating spinal muscular atrophy (SMA) Type 1
4/16/2019
• Ph 3 STR1VE data show prolonged event-free survival, early and rapid increases in CHOP-INTEND and significant milestone achievement in SMA Type 1, consistent with START trial • First-in-human biodistribution data show transduction in intended CNS targets and widespread SMN expression comparable to tissue from unaffected control • More than 150 patients treated with Zolgensma, only 5% of screened patients up to 5 years old excluded due to AAV9 antibody titers greater than 1:50
-
Stealth BioTherapeutics Announces Positive Results for Elamipretide in Barth Syndrome Open-Label Extension Trial
4/16/2019
Design and results from TAZPOWER and the TAZPOWER open-label extension were presented as late-breaking abstracts at the 2019 MDA Clinical & Scientific Conference
-
Sinovac Announces Positive Results From Phase III Trial Of a Sabin Strain-Based Inactivated Polio Vaccine (sIPV) Published in the Journal of Infectious Disease
4/16/2019
The Sinovac-developed sIPV demonstrates both long-term affordability and accessibility and has the potential to contribute significantly to polio eradication in developing countries and the progress towards a polio-free world.
-
First patient dosed in Phase III GEMSTONE-303 study for CS1001 in combination with chemotherapy in first-line gastric adenocarcinoma and gastro-esophageal junction adenocarcinoma
4/16/2019
CStone Pharmaceuticals announces that the first patient has been successfully enrolled and dosed in a Phase III clinical trial assessing CS1001, China's first fully human, full-length anti-PD-L1 antibody, in combination with chemotherapy for the treatment of gastric adenocarcinoma or gastro-esophageal junction adenocarcinoma.
-
Cortexyme Announces Phase 2/3 Clinical Trial Based on Transformational Understanding of Alzheimer’s Disease Now Open for Enrollment
4/16/2019
The GAIN Trial will assess whether a new investigational medicine targeting P. gingivalis bacteria can slow or halt progression of Alzheimer’s disease
-
Polyphor announces enrollment of first patient in PRISM-UDR - the second, FDA agreed - Phase III clinical trial for murepavadin in patients with nosocomial pneumonia
4/16/2019
Murepavadin is the lead, pathogen specific, Phase III antibiotic belonging to the OMPTA family and potentially the first drug of a new class of antibiotics against Gram-negative bacteria in more than 50 years
-
Cambridge, Mass.-based Alnylam Pharmaceuticals indicated that its ENVISION Phase III trial of givosiran was positive for acute hepatic porphyria (AHP).
-
Full Results of Merck’s Zerbaxa Trial Show Drug Is on Par With Meropenem as Pneumonia Treatment
4/15/2019
An analysis of efficacy outcomes by causative pathogens showed that clinical and microbiologic response rates for Zerbaxa were comparable to meropenem for Gram-negative respiratory tract pathogens. -
Janssen Presents Landmark Data From Positive Invokana Trial Halted Early at Australia Conference
4/15/2019
Janssen's Invokana could become the first diabetes medication to demonstrate reduction in progression to end-stage renal failure in Type 2 diabetes patients with chronic kidney disease. -
Alnylam Initiates ILLUMINATE-B Phase 3 Pediatric Study of Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 and Presents New Positive Results from Phase 2 Open-Label Extension Study
4/15/2019
Lumasiran Treatment Resulted in 72 Percent Mean Maximal Reduction in Urinary Oxalate Relative to Phase 1/2 Baseline
-
Arrowhead Pharmaceuticals Receives FDA Clearance to Begin Phase 2/3 Study of ARO-AAT for Treatment of Alpha-1 Liver Disease
4/15/2019
Arrowhead Pharmaceuticals Inc. announced that it has received clearance from the U.S. Food and Drug Administration to proceed with an adaptive Phase 2/3 trial with the potential to serve as a pivotal registrational study of ARO-AAT, the company’s second generation subcutaneously administered RNA interference therapeutic being developed as a treatment for a rare genetic liver disease associated with alpha-1 antitrypsin deficiency.